Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer.
CellSearch®
circulating tumor cell trajectories
circulating tumor cells
liquid biopsy
metastatic colorectal cancer
precision medicine
prognostic and predictive biomarkers
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
16 04 2023
16 04 2023
Historique:
received:
02
03
2023
revised:
13
04
2023
accepted:
14
04
2023
medline:
17
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
A large amount of evidence from clinical studies has demonstrated that circulating tumor cells are strong predictors of outcomes in many cancers. However, the clinical significance of CTC enumeration in metastatic colorectal cancer is still questioned. The aim of this study was to evaluate the clinical value of CTC dynamics in mCRC patients receiving first-line treatments. Serial CTC data from 218 patients were used to identify CTC trajectory patterns during the course of treatment. CTCs were evaluated at baseline, at a first-time point check and at the radiological progression of the disease. CTC dynamics were correlated with clinical endpoints. Using a cut-off of ≥1 CTC/7.5 mL, four prognostic trajectories were outlined. The best prognosis was obtained for patients with no evidence of CTCs at any timepoints, with a significant difference compared to all other groups. Lower PFS and OS were recognized in group 4 (CTCs always positive) at 7 and 16 months, respectively. We confirmed the clinical value of CTC positivity, even with only one cell detected. CTC trajectories are better prognostic indicators than CTC enumeration at baseline. The reported prognostic groups might help to improve risk stratification, providing potential biomarkers to monitor first-line treatments.
Sections du résumé
BACKGROUND
A large amount of evidence from clinical studies has demonstrated that circulating tumor cells are strong predictors of outcomes in many cancers. However, the clinical significance of CTC enumeration in metastatic colorectal cancer is still questioned. The aim of this study was to evaluate the clinical value of CTC dynamics in mCRC patients receiving first-line treatments.
MATERIALS AND METHODS
Serial CTC data from 218 patients were used to identify CTC trajectory patterns during the course of treatment. CTCs were evaluated at baseline, at a first-time point check and at the radiological progression of the disease. CTC dynamics were correlated with clinical endpoints.
RESULTS
Using a cut-off of ≥1 CTC/7.5 mL, four prognostic trajectories were outlined. The best prognosis was obtained for patients with no evidence of CTCs at any timepoints, with a significant difference compared to all other groups. Lower PFS and OS were recognized in group 4 (CTCs always positive) at 7 and 16 months, respectively.
CONCLUSIONS
We confirmed the clinical value of CTC positivity, even with only one cell detected. CTC trajectories are better prognostic indicators than CTC enumeration at baseline. The reported prognostic groups might help to improve risk stratification, providing potential biomarkers to monitor first-line treatments.
Identifiants
pubmed: 37190081
pii: cells12081172
doi: 10.3390/cells12081172
pmc: PMC10136568
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Oncologist. 2012;17(7):947-55
pubmed: 22643538
JAMA. 2021 Feb 16;325(7):669-685
pubmed: 33591350
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
pubmed: 15501967
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84
pubmed: 23836314
Mol Cancer. 2022 Mar 25;21(1):86
pubmed: 35337361
BMC Cancer. 2015 Mar 30;15:202
pubmed: 25880692
Int J Cancer. 2014 Dec 1;135(11):2633-43
pubmed: 24752533
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
Chin J Cancer Res. 2015 Oct;27(5):491-6
pubmed: 26543336
Ann Oncol. 2011 Aug;22(8):1929-30
pubmed: 21633048
Mol Oncol. 2021 Jun;15(6):1647-1666
pubmed: 33289351
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Clin Chem. 2013 Sep;59(9):1384-92
pubmed: 23695297
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Adv Clin Chem. 2018;83:121-181
pubmed: 29304900
J Cancer Res Clin Oncol. 2013 Aug;139(8):1411-6
pubmed: 23736274
Ann Oncol. 2010 May;21(5):1006-12
pubmed: 19861577
J Natl Cancer Inst. 2021 Apr 6;113(4):443-452
pubmed: 32770247
Cancers (Basel). 2019 Jul 24;11(8):
pubmed: 31344798
Genome Med. 2020 Mar 19;12(1):31
pubmed: 32192534
Nat Rev Clin Oncol. 2021 May;18(5):297-312
pubmed: 33473219